Collaboration to leverage VantAI's expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs
VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic...
Roche announced that it has entered into an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology.
Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work...
Enable Medicine, a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer. She succeeds co-founder Sunil Bodapati, who developed Enable Medicine’s strategy and closed Series A financing in 2022. Mr. Bodapati remains Chairman of the Board and will...
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability
BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food...
Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements
Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable...
Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.
The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate...
Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, announced the promotion of Claudio Chuaqui, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Anand Selvaraj, Ph.D. as Vice President and Head of Cancer Biology.
“These leadership updates mark the beginning of a new phase...
Advances in AI Platform Provide an Ability to Rapidly Predict, Identify and Design Biomolecular Structures to Accelerate the Pace and Reduce the Cost of Drug Discovery and Development
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, announced the publication of research in Nature...
Investment underscores Aizon’s leadership position in AI-enhanced pharmaceutical manufacturing and will accelerate growth and launch of next-generation eBR
Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, announced that it has closed $20 million in Series C funding led by NewVale Capital, a growth equity fund that...
ZEPHYRx® and NIOX® announced they have partnered to integrate FeNO by NIOX® into the ZEPHYRx Respiratory Cloud Platform to advance clinical research by offering one source of truth for multiple respiratory endpoints.
ZEPHYRx, a health information technology innovator, has quickly become an industry leader in respiratory monitoring solutions for hybrid clinical research. In...
